income, page-9

something like this.




A steep initial increase (21 mil up on the ?$ we have made on the 400+ sales in Europe, the ? sold in the USA and locally for $????.?? per item) which increases to 29 mill the next year (a 38% increase) and then by another 35 the following year (a 48% increase). Based on these numbers the growth in sales is projected to be increasing considerably for the next few years - no real signs of plateauing off just yet (but these are just projections).

The 84.9 million in 16-17 (or 17-18 if my years are out but still less than 4 years away) equates to 0.04c earning per share (8.4 billion cents for the 1.6 billion shares CURRENTLY  in place). I have read the P/E rations can be calculated on gross earnings (but I may be wrong) but if so, with a range of PE ratios from 10 - 20 (which might be a reasonable guess for a biotech share - most of them have -'ve PE ratios so not many to use as a comparison) a SP of 0.40 - 0.80c is in the realm of possibility. And that is on sales figures of 85 million. at a guestimate of $1000 per patch (a figure between the advertised $1500 per patch and something a lot less to allow for any deals done with hospitals) that will be addressed with 85 000 patches sold. A supply that is in the company has suggested is achievable within 5 years, and, that there very well could be the market to support supply numbers like this Sooner than we think.

A recent post by my good self made reference to the numbers provided by a thoracic surgical association, which suggested that 26000 paediatric cardiac reconstructive procedures performed each year (an association based in the USA, so I anticipate that this may represent the activity in the US alone). Calculating (optimistically) that half of all procedures require a patch , and on average three patches per procedures (both numbers read here on HC so they must be true  - LOL) that could account for almost 40 000 patches for the US alone. The current market place of Europe, the US, Canada and here in aust (when it happens) could potentially have us at the 85 000 sales without any further marketing. Not to mention that each other clinical area (abdominal repair work, vascular, coronary valve) may have the potential to increase the sales equally to that of the very specialised paediatric cardiothoracic community.

The SP hiccoughs of today could very well be a distant memory when the potential of the adapt technology and the associated uptake of the companies products become a reality.